| Autor: |
Vittorio Stefoni, Lisa Argnani, Matteo Carella, Beatrice Casadei, Alice Morigi, Ginevra Lolli, Alessandro Broccoli, Cinzia Pellegrini, Laura Nanni, Paolo Elia Coppola, Pier Luigi Zinzani |
| Přispěvatelé: |
Stefoni V., Argnani L., Carella M., Casadei B., Morigi A., Lolli G., Broccoli A., Pellegrini C., Nanni L., Coppola P.E., Zinzani P.L. |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Journal of cancer research and clinical oncology. |
| ISSN: |
1432-1335 |
| Popis: |
Purpose One of the most critical issues in the management of Hodgkin lymphoma (HL) patients who resulted as primary relapsed or refractory is to obtain a minimal disease status before autologous stem cell transplantation (ASCT). Finding a salvage regimen able to induce this status without severe toxicity would represent a major achievement in this setting. Methods A single‐center retrospective study was conducted to assess effectiveness and safety of BEGEV (bendamustine, gemcitabine, and vinorelbine) regimen as first salvage setting prior to ASCT in HL patients. Results Forty-three patients were treated in our institution between October 2017 and November 2020. Median age at BEGEV therapy was 35.0 years (range 17.2– 70.0), and the median time from frontline therapy to the first cycle of BEGEV was 79.5 days (range 4–2267). At the end of treatment, 31 patients achieved a complete response (CR), with an overall response rate of 76.7%. Forty-one patients harvested CD34+ cells and 35/43 (81.4%) patients underwent ASCT. With a median follow‐up of 22 months, 4 CR patients had disease relapse, yielding an estimated disease-free survival of 73.9% at 34 months. The estimated 2‐year progression-free survival was 66.7%. Response to first-line chemotherapy did not significantly influence prognosis. Conclusions BEGEV regimen was well tolerated, and reversible haematological toxic effects were the most common adverse events. Real-life data on BEGEV regimen as first salvage setting showed a relevant rate of objective responses and a limited myelotoxicity with no impairment of a subsequent mobilization of peripheral blood stem cells. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink